• Xvivo Perfusion received CE certificates for its Heart Assist Transport system, clearing it for clinical use across Europe.
• The technology uses hypothermic oxygenated perfusion to extend preservation time versus ice storage, aiming to lift heart transplant utilization rates.
• Lancet trial data showed a 76% reduction in severe primary graft dysfunction; 12-month follow-up showed 92% survival versus 86% in controls.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xvivo Perfusion AB published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein.